Titan Pharmaceuticals, Inc.
TTNP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $2 |
| % Growth | -100% | -98.3% | -96.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | -$0 | $1 |
| % Margin | – | 100% | -226.7% | 87% |
| R&D Expenses | $0 | $2 | $5 | $6 |
| G&A Expenses | $5 | $6 | $6 | $5 |
| SG&A Expenses | $5 | $6 | $6 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | -$0 | -$0 |
| Operating Expenses | $5 | $7 | $10 | $11 |
| Operating Income | -$5 | -$7 | -$10 | -$9 |
| % Margin | – | -727,700% | -17,058.3% | -613% |
| Other Income/Exp. Net | -$0 | $2 | $0 | $1 |
| Pre-Tax Income | -$5 | -$6 | -$10 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | -$6 | -$10 | -$8 |
| % Margin | – | -556,900% | -16,961.7% | -531.7% |
| EPS | -5.23 | -7.41 | -15.15 | -4.06 |
| % Growth | 29.4% | 51.1% | -273.2% | – |
| EPS Diluted | -5.23 | -7.41 | -15.15 | -4.06 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 2 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$5 | -$7 | -$10 | -$9 |
| % Margin | – | -716,500% | -16,731.7% | -598.5% |